Patents by Inventor Simon Warby

Simon Warby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective Reduction of Allelic Variants
    Publication number: 20200377946
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: January 14, 2020
    Publication date: December 3, 2020
    Applicants: Ionis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20180291453
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: December 18, 2017
    Publication date: October 11, 2018
    Applicants: Ionis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20150292015
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: March 3, 2015
    Publication date: October 15, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • Methods and compositions for the treatment of huntington's disease
    Patent number: 9157120
    Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: October 13, 2015
    Assignee: The University of British Columbia
    Inventors: Michael Hayden, Jeffrey Carroll, Simon Warby
  • Selective reduction of allelic variants
    Patent number: 9006198
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 14, 2015
    Assignees: Isis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
    Publication number: 20140256578
    Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.
    Type: Application
    Filed: February 6, 2014
    Publication date: September 11, 2014
    Applicant: The University of British Columbia
    Inventors: Michael HAYDEN, Jeffrey CARROLL, Simon WARBY
  • Methods and compositions for the treatment of Huntington'S disease
    Patent number: 8679750
    Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: March 25, 2014
    Assignee: The University of British Columbia
    Inventors: Michael Hayden, Jeffrey Carroll, Simon Warby
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20130046008
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: February 8, 2011
    Publication date: February 21, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
    Publication number: 20110213010
    Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.
    Type: Application
    Filed: May 8, 2009
    Publication date: September 1, 2011
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Michael Hayden, Jeffrey Carroll, Simon Warby